Common plasma protein marker LCAT in aggressive human breast cancer and canine mammary tumor
- Authors
- Park, Hyoung-Min; Kim, HuiSu; Kim, Dong Wook; Yoon, Jong-Hyuk; Kim, Byung-Gyu; Cho, Je-Yoel
- Issue Date
- Dec-2020
- Publisher
- KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY
- Keywords
- Biomarker; Breast cancer; Comparative medicine; Prognostic; Proteomics
- Citation
- BMB REPORTS, v.53, no.12, pp.664 - 669
- Journal Title
- BMB REPORTS
- Volume
- 53
- Number
- 12
- Start Page
- 664
- End Page
- 669
- URI
- http://scholarworks.bwise.kr/kbri/handle/2023.sw.kbri/558
- DOI
- 10.5483/BMBRep.2020.53.12.238
- ISSN
- 1976-6696
- Abstract
- Breast cancer is one of the most frequently diagnosed cancers. Although biomarkers are continuously being discovered, few specific markers, rather than classification markers, representing the aggressiveness and invasiveness of breast cancer are known. In this study, we used samples from canine mammary tumors in a comparative approach. We subjected 36 fractions of both canine normal and mammary tumor plasmas to high-performance quantitative proteomics analysis. Among the identified proteins, LCAT was selectively expressed in mixed tumor samples. With further MRM and Western blot validation, we discovered that the LCAT protein is an indicator of aggressive mammary tumors, an advanced stage of cancer, possibly highly metastatic. Interestingly, we also found that LCAT is overexpressed in high-grade and lymph-node-positive breast cancer in silico data. We also demonstrated that LCAT is highly expressed in the sera of advanced-stage human breast cancers within the same classification. In conclusion, we identified a possible common plasma protein biomarker, LCAT, that is highly expressed in aggressive human breast cancer and canine mammary tumor.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 연구본부 > 퇴행성 뇌질환 연구그룹 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.